Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.Am J Hum Genet. 2003; 72: 1117-1130
- Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer.J Natl Cancer Inst. 2015; 107
- Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population.J Clin Oncol. 2015; 33: 2901-2907
- Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time?.Cancer Lett. 2020; 468: 59-71
- Initiation of a formalized precision medicine program in gynecologic oncology.Gynecol Oncol. 2016; 141: 24-28
- Molecular guided treatments in gynecologic oncology: analysis of a real-world precision cancer medicine platform.Oncologist. 2020; 25: e1060-e1069
- Integrated genomic analyses of ovarian carcinoma.Nature. 2011; 474: 609-615
- Integrated genomic characterization of endometrial carcinoma.Nature. 2013; 497: 67-73
- Integrated genomic and molecular characterization of cervical cancer.Nature. 2017; 543: 378-384
- Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.J Clin Oncol. 2010; 28: 3570-3576
- Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.Breast Cancer Res. 2014; 16: 1-11
- Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer.Cancer Discov. 2015; 5: 1137-1154
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.Lancet Oncol. 2016; 17: 1579-1589
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial.Lancet Oncol. 2017; 18: 75-87
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol. 2019; 20: 636-648
- Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial.J Clin Oncol. 2019; 37: 2968-2973
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 390: 1949-1961
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2017; 18: 1274-1284
- Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.N Engl J Med. 2018; 379: 2495-2505
- Niraparib in patients with newly diagnosed advanced ovarian cancer.N Engl J Med. 2019; 381: 2391-2402
- Olaparib plus bevacizumab as first-line maintenance in ovarian cancer.New Engl J Med. 2019; 381: 2416-2428
- Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.J Clin Oncol. 2011; 29: 3008-3015
- Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.J Pathol. 2013; 229: 422-429
- Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer.J Natl Cancer Inst. 2016; 108
- BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma.Cancer Discov. 2019; 9: 210-219
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.Lancet Oncol. 2013; 14: 134-140
- BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.Cancer. 2013; 119: 548-554
- Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.J Natl Cancer Inst. 2003; 95: 484-486
- A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer.Gynecol Oncol. 2020; 159: 22
- Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.Clin Cancer Res. 2008; 14: 5198-5208
- Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer.Cell Rep. 2020; 31: 107502
- Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes.Clin Cancer Res. 2017; 23: 4077-4085
- The mutational landscape of endometrial cancer.Curr Opin Genet Dev. 2015; 30: 25-31
- Integrated genomic characterization of endometrial carcinoma.Nature. 2013; 497: 67-73
- FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors.Clin Cancer Res. 2019; 25: 3753
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.J Clin Oncol. 2020; 38: 2981-2992
- 354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study.J ImmunoTherapy Cancer. 2021; 9: A381
- Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial.JAMA Oncol. 2020; 6: 1766-1772
- HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study.Histopathology. 2010; 56: 269-273
- An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2008; 108: 3-9
- Overexpression of HER-2/neu in uterine serous papillary cancer.Clin Cancer Res. 2002; 8: 1271-1279
- Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu.J Clin Oncol. 2018; 36: 2044-2051
- Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx.J Clin Oncol. 2017; 35: e14589
- Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study.J Clin Oncol. 2019; 37: 1470-1478
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020; 21: 1353-1365
- Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.N Engl J Med. 2021; 385: 1856-1867
- NCI dictionary of cancer terms. National Cancer Institute, 2020
- Cetuximab in patients with breast cancer, non-small cell lung cancer, and ovarian cancer without KRAS, NRAS, or BRAF mutations: results from the targeted agent and profiling utilization registry (TAPUR) study.Targeted Oncol. 2020; 15: 733-741
- Engineered antibody–drug conjugates with defined sites and stoichiometries of drug attachment.Protein Eng Des Sel. 2006; 19: 299-307
- Antibody-drug conjugates.mAbs. 2014; 6: 15-17
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.Ann Oncol. 2021; 32: 757-765
ImmunoGen, Immunogen announces positive top-line results from pivotal SORAYA trial of mirvetuximab soravtansine in ovarian cancer. 2021. Available at: https://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-positive-top-line-results-pivotal-soraya. Accessed December 17, 2021.
- A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-343 resistant ovarian cancer (OC).J Clin Oncol. 2014; 32: 2504
- Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-347 resistant ovarian cancer in a randomized, open-label, phase II study.Ann Oncol. 2018; 29: 917-923
- Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-350 targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.J Clin Oncol. 2019; 37: 3010
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (InnovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.Lancet Oncol. 2021; 22: 609-619
Article info
Publication history
Published online: April 07, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
